Trial Profile
An prospective, single-arm, multi-center clinical trial of Apatinib combined with capecitabine in the treatment of advanced ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine
- Indications Ovarian cancer
- Focus Therapeutic Use
- 03 Aug 2017 New trial record